FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats [PDF]
Cells, 2022 The immunophilin FKBP51, the angiomotin AmotL2, and the scaffoldin IQGAP1 are overexpressed in many types of cancer, with the highest increase in leucocytes from patients undergoing oxaliplatin chemotherapy.
Rebeca González-Fernández +5 more
doaj +3 more sources
Case Report: Delayed-type hypersensitivity reaction to meropenem in an elderly patient—successful management with imipenem-cilastatin [PDF]
Frontiers in MedicineMeropenem is a clinically essential carbapenem antibiotic with a broad antimicrobial spectrum, potent antibacterial efficacy, and high stability against β-lactamase, which plays a pivotal role in anti-infective therapy.
Cuilin He +5 more
doaj +4 more sources
Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in Pseudomonas aeruginosa Isolates from Sepsis [PDF]
Microorganisms, 2023 Pseudomonas aeruginosa is among the most ubiquitous bacteria in the natural world, exhibiting metabolic and physiological versatility, which makes it highly adaptable.
Telma de Sousa +6 more
doaj +3 more sources
Nephroprotective Effects of Cilastatin in People at Risk of Acute Kidney Injury: A Systematic Review and Meta-analysis [PDF]
Kidney MedicineRationale & Objective: Cilastatin is an inhibitor of drug metabolism in the proximal tubule that demonstrates nephroprotective effects in animals.
Dilaram Acharya +9 more
doaj +3 more sources
Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity [PDF]
CellsOxaliplatin-induced peripheral neurotoxicity (OIPN) represents a major challenge in cancer therapy, characterized by dorsal root ganglia (DRG) inflammation and disruption of neuro-glio-vascular unit function.
Rita Martín-Ramírez +7 more
doaj +3 more sources
Infection and Drug Resistance, 2015 Wissam K Kabbara, George T Nawas, Wijdan H RamadanDepartment of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon Background: Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that
Kabbara WK, Nawas GT, Ramadan WH
doaj +3 more sources
Acta Pharmaceutica Sinica B, 2019 Imipenem is a carbapenem antibiotic. However, Imipenem could not be marketed owing to its instability and nephrotoxicity until cilastatin, an inhibitor of renal dehydropeptidase-I (DHP-I), was developed.
Xiaokui Huo +9 more
doaj +2 more sources
Imipenem–cilastatin-induced thrombocytosis: A probable rare case report
European Journal of Inflammation, 2022 Drug-induced thrombocytosis is difficult to identify and is rarely reported. Here, we report a probable rare case of imipenem–cilastatin-induced thrombocytosis in a 51-year-old female.
Huadong Chen +3 more
doaj +2 more sources
Scientific Reports, 2021 Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity,
Masashi Arita +21 more
doaj +2 more sources
Antioxidants, 2020 Gentamicin is a used antibiotic that causes nephrotoxicity in 10–20% of treatment periods, which limits its use considerably. Our results have shown that cilastatin may be a promising therapeutic alternative in toxin-induced acute kidney injury (AKI ...
Juan Carlos Jado +9 more
doaj +2 more sources